Please assess the completion status of the following clinical trial:

Trial Title: A Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Study Of PF-06700841, With Bioavailability/Food Effect Investigation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~Key Inclusion Criteria for Healthy Subject Cohorts:~* Healthy male subjects and/or female subjects of non-childbearing potential between the ages of 18 and 55 years, inclusive~* No evidence of active or latent or inadequately treated infection with Mycobacterium tuberculosis (TB)~Key Inclusion Criteria for Psoriasis Subject Cohorts:~* Male subjects and/or female subjects of non-childbearing potential with a diagnosis of plaque psoriasis who are between the ages of 18 and 65 years, inclusive~* Have a diagnosis of plaque psoriasis for at least 6 months prior to first study dose~Exclusion Criteria:~Key Exclusion Criteria for Healthy Subject Cohorts:~* Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at time of dosing)~* Males of childbearing potential who are unwilling or unable to use a highly effective method of contraception as outlined in this protocol for the duration of the study and for at least 28 days after the last dose of investigational product~Key Exclusion Criteria for Psoriasis Subject Cohorts:~* Currently have non plaque forms of psoriasis, (eg, erythrodermic, guttate, or pustular psoriasis).~* Have current drug induced psoriasis, eg, a new onset of psoriasis or an exacerbation of psoriasis from beta blockers, calcium channel blockers, antimalarial drugs or lithium~* Males of childbearing potential who are unwilling or unable to use a highly effective method of contraception as outlined in this protocol for the duration of the study and for at least 28 days after the last dose of investigational product

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- PF-06700841 Oral Solution/Suspension (Type: EXPERIMENTAL): None
- PF-06700841 Tablet (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): Oral placebo comparator for the healthy subject single and multiple ascending dose periods, and the psoriasis multiple dose period. No placebo used for the bioavailability investigation.

Based on this trial design, predict the completion outcome and termination type (if applicable).